The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Dec 2017 11:28

RNS Number : 4713A
Redx Pharma plc
28 December 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Redx Pharma

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Lanstead Capital LP

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

20/12/2017

6. Date on which issuer notified (DD/MM/YYYY):

27/12/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

7.61%

0.00%

7.61%

126,477,914

Position of previous notification (if

applicable)

9.55%

0.00%

9.55%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares of £0.01

 

ISIN: GB00BSNB6S51

9,625,000

7.61%

SUBTOTAL 8. A

9,625,000

7.61%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

N/A

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Salt Lake City, United States

Date of completion

27/12/2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBBBDDSDDBGRI
Date   Source Headline
13th Apr 201612:06 pmRNSResult of General Meeting and Issue of Equity
4th Apr 20162:58 pmRNSGrant of Options
4th Apr 201612:59 pmRNSResult of General Meeting
4th Apr 20167:00 amRNSIssue of Equity
29th Mar 20167:00 amRNSDirector/PDMR Shareholding
24th Mar 20161:55 pmRNSPlacing to Raise £10 Million
8th Mar 20167:00 amRNSChange of Adviser
24th Feb 201612:39 pmRNSResult of AGM
24th Feb 20167:00 amRNSAGM Statement
22nd Jan 20169:09 amRNSHardman & Co Research Report: Pipeline progress
22nd Jan 20167:30 amRNSHardman & Co Research Report: Pipeline progress
20th Jan 20167:00 amRNSFinal Results
6th Jan 20167:00 amRNSNotice of Results
4th Jan 20167:00 amRNSAppointment of Non-Executive Director
3rd Dec 20157:00 amRNSFourth drug development candidate
10th Nov 20157:00 amRNSRe BioInfect Conference 2015
5th Nov 20157:00 amRNSSenior management appointments
23rd Oct 20152:57 pmRNSRe Review on Antimicrobial Resistance
1st Oct 20157:00 amRNSTrading Update
3rd Sep 20157:00 amRNSCancer Research Collaboration with Redx Pharma
3rd Sep 20157:00 amRNSCancer Research Collaboration
22nd Jun 20157:00 amRNSHalf Yearly Report
19th Jun 20155:14 pmRNSHolding(s) in Company
4th Jun 20159:45 amRNSHolding(s) in Company
2nd Jun 20157:00 amRNSDiscovery of breakthrough MRSA compound
26th May 20157:01 amRNSSecond drug development candidate identified
14th May 20157:00 amRNSRe Review on Antimicrobial Resistance
14th May 20157:00 amRNSLaunch of third subsidiary, Redx Immunology
11th May 20157:00 amRNSPre-Clinical Proof of Concept with Oncology Lead
31st Mar 20155:13 pmRNSHolding(s) in Company
31st Mar 20151:35 pmRNSHolding(s) in Company
31st Mar 20151:33 pmRNSHolding(s) in Company
31st Mar 20159:37 amRNSHolding(s) in Company
27th Mar 20157:00 amRNSAdmission to AIM and First Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.